CheckMate 214 nivolumab ipilimumab or sunitinib in patients with advanced renal cell carcinoma

CheckMate 214: nivolumab ipilimumab or sunitinib in patients with advanced renal cell carcinoma

21:27 EST 16 Feb 2019 | ecancermedicalscience

Prof Nizar Tannir speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about a thirty month follow up from the CheckMate 214 trial. He begins by outlining the preliminary data for the trial, and then how the follow up data compared with...

More From BioPortfolio on "CheckMate 214: nivolumab ipilimumab or sunitinib in patients with advanced renal cell carcinoma"